185692-85-7

Usage

Uses

1. Used in Pharmaceutical Industry:
[(1S)-2-[[(tert-Butyl)diMethylsilyl]oxy]-1-(hydroxyMethyl)ethyl]-carbaMic Acid tert-Butyl Ester is used as an intermediate in the synthesis of Chloramphenicol (C325030) for its role in producing antibiotics that are effective against a range of bacterial infections.
2. Used in Chemical Synthesis:
[(1S)-2-[[(tert-Butyl)diMethylsilyl]oxy]-1-(hydroxyMethyl)ethyl]-carbaMic Acid tert-Butyl Ester is used as a reagent in the chemical synthesis of various organic compounds due to its unique functional groups and stereochemistry, which can be exploited to create a diverse array of molecules with different applications.
3. Used in Research and Development:
[(1S)-2-[[(tert-Butyl)diMethylsilyl]oxy]-1-(hydroxyMethyl)ethyl]-carbaMic Acid tert-Butyl Ester is utilized in research and development for studying the properties and reactivity of complex organic molecules, as well as for the development of new synthetic methods and techniques in organic chemistry.
4. Used in Material Science:
[(1S)-2-[[(tert-Butyl)diMethylsilyl]oxy]-1-(hydroxyMethyl)ethyl]-carbaMic Acid tert-Butyl Ester may also find applications in material science, particularly in the development of new materials with specific properties, such as improved stability or reactivity, by incorporating [(1S)-2-[[(tert-Butyl)diMethylsilyl]oxy]-1-(hydroxyMethyl)ethyl]-carbaMic Acid tert-Butyl Ester into their structure.

Upstream product

• 112418-19-6 (R)-2-N-tert-butoxycarbonylamino-3-(tert-butyldimethylsilyloxy)propionic acid methyl ester 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 95715-85-8 2-(tert-butoxycarbonylamino)-3-hydroxypropionic acid methyl ester 

Downstream Products

• 217661-62-6 [(1R,2R)-1-(tert-Butyl-dimethyl-silanyloxymethyl)-2-hydroxy-2-phenyl-ethyl]-carbamic acid tert-butyl ester 
• 1009093-14-4 ((1R,2R)-2-hydroxy-1-hydroxymethyl-2-phenylethyl)carbamic acid tert-butyl ester 
• 217661-64-8 Acetic acid (1R,2R)-3-acetoxy-2-tert-butoxycarbonylamino-1-phenyl-propyl ester 
• 950690-19-4 ethyl (S)-5-((tert-butoxycarbonyl)amino)cyclohexa-1,3-diene-1-carboxylate 
• 90242-16-3 (5S)-5-<(tert-butoxycarbonyl)amino>cyclohexadienecarboxylic acid 

Relevant academic research and scientific papers

CYCLIC COMPOUNDS AND METHODS OF USING SAME

The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acc

Structure-activity relationships of lysophosphatidylserine analogs as agonists of G-protein-coupled receptors GPR34, P2Y10, and GPR174

Lysophosphatidylserine (LysoPS) is an endogenous lipid mediator generated by hydrolysis of membrane phospholipid phosphatidylserine. Recent ligand screening of orphan G-protein-coupled receptors (GPCRs) identified two LysoPS-specific human GPCRs, namely, P2Y10 (LPS2) and GPR174 (LPS3), which, together with previously reported GPR34 (LPS1), comprise a LysoPS receptor family. Herein, we examined the structure-activity relationships of a series of synthetic LysoPS analogues toward these recently deorphanized LysoPS receptors, based on the idea that LysoPS can be regarded as consisting of distinct modules (fatty acid, glycerol, and l-serine) connected by phosphodiester and ester linkages. Starting from the endogenous ligand (1-oleoyl-LysoPS, 1), we optimized the structure of each module and the ester linkage. Accordingly, we identified some structural requirements of each module for potency and for receptor subtype selectivity. Further assembly of individually structure-optimized modules yielded a series of potent and LysoPS receptor subtype-selective agonists, particularly for P2Y10 and GPR174.

Morita-Baylis-Hillman approach toward formal total synthesis of tamiflu and total synthesis of gabaculine

A Morita-Baylis-Hillman reaction mediated approach to the formal total synthesis of oseltamivir and the total synthesis of gabaculine is described. This strategy involves the enantiocontrolled preparation of Corey's intermediate in 22 % yield, which is pr

CYCLIZED DERIVATIVES AS EG-5 INHIBITORS

The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds: (I).

SUBSTITUTED AMIDE BETA SECRETASE INHIBITORS

Disclosed are novel compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4 and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering to a patient I need of such treatment a combination of at least one compound of formula (I) and at least one compound selected from the group consisting of β-secretase inhibitors other than those of formula (I), HMG-CoA reductase inhibitors, gamma-secretase inhibitors, non-steroidal anti-inflammatory agents, N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors and anti-amyloid antibodies.

MACROCYCLIC BETA-SECRETASE INHIBITORS

Disclosed are novel compounds of the formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, n and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering to a patient I need of such treatment a combination of at least one compound of formula (I) and at least one compound selected from the group consisting of -secretase inhibitors other than those of formula (I), HMG-CoA reductase inhibitors, gamma-secretase inhibitors, non-steroidal anti-inflammatory agents, N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors and anti-amyloid antibodies.